Zacks Research Has Bullish Outlook for GSK FY2027 Earnings

GSK plc (NYSE:GSK) – Equities research analysts at Zacks Research boosted their FY2027 EPS estimates for shares of GSK in a research report issued to clients and investors on Tuesday, March 25th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings of $5.05 per share for the year, up from their prior estimate of $5.04. The consensus estimate for GSK’s current full-year earnings is $4.14 per share.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%.

A number of other analysts also recently issued reports on the company. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Morgan Stanley initiated coverage on shares of GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Up 0.6 %

GSK opened at $38.74 on Thursday. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK has a one year low of $31.72 and a one year high of $45.93. The firm has a market capitalization of $80.19 billion, a P/E ratio of 24.37, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The company has a fifty day moving average price of $37.22 and a 200-day moving average price of $36.79.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GSK. Dodge & Cox lifted its position in GSK by 0.5% in the fourth quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company’s stock valued at $2,314,672,000 after purchasing an additional 353,749 shares during the last quarter. FMR LLC raised its holdings in GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock valued at $1,786,475,000 after buying an additional 23,814,104 shares during the last quarter. Primecap Management Co. CA grew its holdings in GSK by 70.1% in the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after acquiring an additional 10,407,905 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock valued at $637,061,000 after acquiring an additional 259,867 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of GSK by 0.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company’s stock worth $255,914,000 after purchasing an additional 35,134 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a yield of 4.06%. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio is presently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.